• Please log in or register to access this feature.

Research Article

You have free access to this content

A stochastic model for survival of early prostate cancer with adjustments for leadtime, length bias, and over-detection

  1. Grace Hui-Min Wu1,2,
  2. Anssi Auvinen1,3,
  3. Amy Ming-Fang Yen2,4,
  4. Matti Hakama1,3,
  5. Stephen D. Walter5,
  6. Hsiu-Hsi Chen2,*

Article first published online: 23 DEC 2011

DOI: 10.1002/bimj.201000107

Issue

Biometrical Journal

Biometrical Journal

Special Issue: Survival and Event History Analysis

Volume 54, Issue 1, pages 20–44, January 2012

Additional Information

How to Cite

Wu, G. H.-M., Auvinen, A., Yen, A. M.-F., Hakama, M., Walter, S. D. and Chen, H.-H. (2012), A stochastic model for survival of early prostate cancer with adjustments for leadtime, length bias, and over-detection. Biom. J., 54: 20–44. doi: 10.1002/bimj.201000107

Author Information

  1. 1

    Tampere School of Public Health, University of Tampere, Tampere, Finland

  2. 2

    Division of Biostatistics, Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan

  3. 3

    Finnish Cancer Institute, Helsinki, Finland

  4. 4

    School of Oral Hygiene, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan

  5. 5

    Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada

*Phone: +886-2-33668033, Fax: +886-2-23587707

Publication History

  1. Issue published online: 5 JAN 2012
  2. Article first published online: 23 DEC 2011
  3. Manuscript Accepted: 3 OCT 2011
  4. Manuscript Revised: 1 OCT 2011
  5. Manuscript Received: 9 MAY 2010

Funded by

  • Finnish Distinguished Professor (FiDiPro) Academy of Finland, Tampere University Hospital Research Fund
  • Taiwan National Science Council. Grant Numbers: NSC 91-2320-B-002-215, NSC 94-2314-B-002-106, NSC 97-2314-B-002-019-MY3

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (431K)

References

  • Albertsen, P. C., Hanley, J. A. and Fine, J. (2005). 20-year outcomes following conservative management of clinically localized prostate cancer. Journal of American Medical Association 293, 2095–210.
  • Auvinen, A., Määttänen, L., Stenman, U. H., Tammela, T., Rannikko, S., Aro, J., Juusela, H. and Hakama, M. (2002). Lead-time in prostate cancer screening (Finland). Cancer Causes Control 13, 279–285.
  • Brenner, H. and Arndt, V. (2005). Long-term survival rates of patients with prostate cancer in the prostate-specific antigen era. Journal of Clinical Oncology 23, 441–447.
  • Chen, T. H. H., Kuo, H. S., Yen, M. F., Lai, M. S., Tabar, L. and Duffy, S. W. (2000). Estimation of sojourn time in chronic disease screening without data on interval cases. Biometrics 56, 167–172.
    Direct Link:
  • Cox, D. R. and Miller, H. D. (1965). The Theory of Stochastic Processes. Methuen, London.
  • Day, N. E. and Walter, S. D. (1984), Simplified models of screening for chronic disease: estimation procedures from mass screening programmes. Biometrics 40, 1–14.
  • Dempster, A. P., Laird, N. M. and Rubin, D. B. (1977). Maximum likelihood from incomplete data via the EM algorithm. Journal of the Royal Statistical Society: Series B 39, 1–38.
  • Draisma, G., Boer, R., Otto, S. J., van der Cruijsen, I. W., Damhuis, R. A. M, Schröder, F. H. and de Koning, H. J. (2003). Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. Journal of the National Cancer Institute 95, 868–878.
  • Draisma, G. and de Koning, H. J. (2003). MISCAN: estimating lead-time and over-detection by simulation. British Journal of Urology International 92, 106–111.
    Direct Link:
  • Efstathiou, J. A., Chen, M. H., Catalona, W. J., McLeod, D. G., Carroll, P. R., Moul, J. W., Roehl, K. A. and D'Amico, A. V. (2006). Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. Urology 68, 342–347.
  • Etzioni, R., Penson, D. F., Legler, J. M., di Tommaso, D., Boer, R., Gann, P. H. and Feuer, E. J. (2002). Overdiagnosis in prostate specific antigen screening: lessons from US prostate cancer incidence trends. Journal of the National Cancer Institute 94, 981–990.
  • Finne, P., Stenman, U. -H., Määttänen, L., Mäkinen, T., Tammela, T., Martikainen, P., Ruutu, M., Ala-Opas, M., Aro, J., Karhunen, P., Lahtela, J., Rissanen, P., Juusela, H., Hakama, M. and Auvinen, A. (2003). The Finnish trial of prostate cancer screening: where are we now? British Journal of Urology International 92, 22–26.
    Direct Link:
  • Gann, P. H., Hennekens, C. H. and Stampfer, M. J. (1995). A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer. Journal of the American Medical Association 273, 289–294.
  • Hugosson, J., Aus, G., Becker, C., Carlsson, S., Eriksson, H., Lilja, H., Lodding, P. and Tibblin, G. (2000). Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden. British Journal of Urology International 85, 1078–1084.
    Direct Link:
  • Jang, T. L., Han, M., Roehl, K. A., Hawkins, S. A. and Catalona, W. J. (2006). More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study. Urology 67, 343–348.
  • Johansson, J. E., Holmberg, L., Johansson, S., Bergström, R. and Adami, H. O. (1997). Fifteen-year survival in prostate cancer: a prospective, population-based study in Sweden. Journal of the American Medical Association 277, 467–471.
  • Johansson, J. E., Andren, O., Andersson, S. O., Dickman, P. W., Holmberg, L., Magnuson, A. and Adami, H. -O. (2004). Natural history of early, localized prostate cancer. Journal of the American Medical Association 291, 2713–2719.
  • Morrison, A. S. (1985). Screening in Chronic Disease. Oxford University Press, New York.
  • Paquette, E. L., Sun, L., Paquette, L. R., Connelly, R., Mcleod, D. G. and Moul, J. W. (2002). Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. Urology 60, 756–759.
  • Quaglia, A., Vercelli, M., Puppo, A., Casella, C., Artioli, E., Crocetti, E., Falcini, F., Ramazzotti, V., Tagliabue, G. and the Prostate Working Group (2003). Prostate cancer in Italy before and during the ‘PSA era’: survival trend and prognostic determinants. European Journal of Cancer Prevention 12, 145–152.
  • Stenman, U. H., Leinonen, J., Hakama, M., Knekt, P., Aromaa, A. and Teppo, L. (1994). Serum concentrations of prostate specific antigen and its complex with alpha1–antichymotrypsin before diagnosis of prostate cancer. Lancet 344, 1594–1598.
  • Tarone, R. R., Cho, K. C. and Brawley, O. W. (2000). Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology 11, 167–170.
  • Törnblom, M., Eriksson, H., Franzén, S., Gustafsson, O., Lilja, H., Norming, U. and Hugosson, J. (2004). Lead time associated with screening for prostate cancer. International Journal of Cancer 108, 122–129.
    Direct Link:
  • Ung, J. O., Richie, J. P., Chen, M. H., Renshaw, A. A. and D'Amico, A. V. (2002). Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology 60, 458–463.
  • Walter, S. D. and Stitt, L. W. (1987). Evaluating the survival of cancer cases detected by screening. Statistics in Medicine 6, 885–900.
    Direct Link:
  • World Cancer Report (2003). IARC, France.
  • Wu, H. M., Yen, M. F. and Chen, T. H. H. (2004). SAS macro program for non-homogeneous Markov process in modeling multi-state disease progression. Computer Methods and Programs in Biomedicine 75, 95–105.
View Full Article (HTML) Get PDF (431K)